2-(5-chloropyridin-2-yloxy)-2-methylpropanamide | 1252672-72-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(5-chloropyridin-2-yloxy)-2-methylpropanamide
• 英文别名: 2-[(5-chloro-2-pyridinyl)oxy]-2-methylPropanamide；2-(5-chloropyridin-2-yl)oxy-2-methylpropanamide
• CAS: 1252672-72-2
• 化学式: C₉H₁₁ClN₂O₂
• 分子量: 214.652
• InChiKey: UIGOTVXBZIEUAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF
  申请人：Peddi Sridhar

  公开号：US20100267738A1

  公开（公告）日：2010-10-21

  The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

  本发明涉及11-β-羟基类固醇脱氢酶类型1酶的抑制剂及其在治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征、中枢神经系统疾病以及与过多糖皮质激素相关的疾病和病况中的应用。
• Novel amide and amidine derivates and uses thereof
  申请人：Abbott Laboratories

  公开号：EP2243479A2

  公开（公告）日：2010-10-27

  The present invention relates to inhibitors of 11- β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

  本发明涉及11-β-羟类固醇脱氢酶1型酶的抑制剂及其在治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、血脂紊乱、代谢综合征、中枢神经系统紊乱以及与糖皮质激素过多有关的疾病和病症中的用途。
• US8507493B2
  申请人：——

  公开号：US8507493B2

  公开（公告）日：2013-08-13
• [EN] NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS AMIDE ET AMIDINE ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2010123838A2

  公开（公告）日：2010-10-28

  The present invention relates to inhibitors of 11- β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.